Bitcoin SV (BSV) surged more than 14% on September 23, driven by concentrated trading activity on Asian exchanges, especially Upbit. Despite the price rise to around $22.50, derivatives data shows the market remains vulnerable to selling pressure due to positive funding rates and mixed netflows. The rally lacks a clear event catalyst, making its sustainability dependent on continued buying to absorb selling. Market sentiment is bullish, but investors should watch for potential reversals given the elevated derivatives participation.
Bitcoin SV's recent surge accompanies a day where 36 of 50 major cryptocurrencies on Pluang rose as of Sep 23, 2026 17:51 WIB. For readers following the broader crypto market, here is Pluang's snapshot: SNX gained 11.82% to Rp4.683 with a typical hold time of 69 days and a 92% sell order activity; COTI rose 11.71% to Rp296 with a 78% buy order activity and a 120-day hold; ONE fell 11.43% to Rp56, with a balanced sell/buy order split and a 152-day hold time. This data reflects diverse trading dynamics across the sector on that date.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
